source data modellers perspectives
play

SOURCE DATA Modellers perspectives Session 2 : Structure, methods and decision criteria for extrapolation (planning) Mapping of the extrapolation with the common framework to clinicians, modelling and stats Extrapolation workshop; 30/9-2015

0 downloads 1 Views 609 KB Size Report
  1. SOURCE DATA Modellers perspectives Session 2 : Structure, methods and decision criteria for extrapolation (planning) Mapping of the extrapolation with the common framework to clinicians, modelling and stats Extrapolation workshop; 30/9-2015

  2. Sources of data In general; all data relevant for describing the interplay between the drug, organism and disease (“systems data”) Useful sources of data include • Clinical data • Adult clinical data on drug in question • Paediatric clinical data on drug in question • Clinical data on same drug in other conditions • Clinical data from other similar drugs in same condition. • Non clinical data • In vitro data/ Physiochemical drug data • Data on biology, physiology, pathophysiology etc The sources needed will generally depend on the approaches taken • Need to outline the potential sources per approach? • Is there a need to set general requirements?

  3. Inform transitions Relevant levels of transition in paediatric developments: • Inform clinical study design or replace a study • Source to target population • adult to children • between children of different age groups • animal to human • physiochemical and in vitro to in vivo • Dose to Exposure • Exposure to Response • exposure to PD endpoint/biomarker • PD endpoint/biomarker to clinical efficacy and safety endpoints

  4. Dose Exposure Response approaches Clinical Data/ POPPK or PBPK POPPKPD or systems models time course models Concentration/amount Signalling of active D rug in effect Response + R D-R pathway/ compartment endpoint MOA Disease status Concentration/amount Biomarkers of active drug in central Dose Disease progression (measureable) Maturation... compartment Placebo effect Compliance Covariates: Disease Size Study methodology Co-medication kel (DDIs) Maturation... Sample power Nutrition Formulation Covariates: Pharmacogenetics Other… Disease Ethnicity Co-meds Nutrition Safety Formulation PGx endpoint Ethnicity Dose Exposure PD Efficacy and safety Response Different data sources and confidence in the data.

  5. Tool box for pharmacological M&S Top-down Bottom-up Population PK and PD PBPK and PD Bayesian Systems pharmacology Combine methods to use all existing knowledge Clinical trial simulations to optimize trial design

  6. Population PKPD- Data sources Primary data source : Clinical data: Pharmacokinetics Pharmacodynamics Covariate data Supporting data : Possible determinants of Inter-subject Physiological data: on clearance, Vd variability: and F to support PK model Age, Body Weight or Surface Systems data/ in vitro data to support Area, gender, race PKPD model Genetic: CYP2D6, CYP2C19 Factors linked to variability Renal (Creatinine Clearance) or Assumptions Hepatic impairment, Disease State Uncertainty Concomitant Drugs Other Factors: Diet, Circadian Variation, Formulations

  7. PBPK/System modelling System model Drug specific parameters Anatomy ADME, PK, PD and MOA Biology Metabolism Physiology Active transport/Passive diffusion Pathophysiology Protein binding Patient/disease extrinsic factors Drug-drug interactions Receptor binding 7

  8. Systems models - data sources Property In silico In vitro In vivo Drug dependent Drug and dose form properties Physiological data √ √ √ parameters Log D √ √ Acid or base √ √ pKa • Variety of sources √ √ √ • Variety of sources Solubility • Historical Drug distribution parameters • Non standardised in √ √ Plasma protein binding • Data often lacking √ √ vitro assays Blood/Plasma partitioning • Populations in software • No incorporation of √ √ Microsome binding reflect variability in √ √ √ variability Permeability physiology/ enzymology. √ √ √ Tissue Kp’s • Complex pathways Pharmacokinetic parameters √ √ √ Volume of distribution √ √ √ Plasma clearance √ √ Clearance (renal) √ √ Clearance (metabolic) √ √ Clearance (active) √ √ √ Oral bioavailability √ √ √ Gut extraction √ √ √ First pass hepatic extraction Pharmacodyamics- Multiple pathways √ √ √ Vmax √ √ √ Km √ √ √ Time dependancy

  9. Extended time course models Limited longer term clinical data: • 1358 patients at 12 weeks Extensive clinical data • 270 patients at 60 weeks • 5102 patients • 89,760 patient years of data

  10. Conclusions • The source of data depends on the transition being made and the approach being used. • All data should be considered that describes the interplay between the drug, the subject and the disease. • Requirement for transparency about the source of the data. • Systems modelling is important for a thorough mechanistic understanding but uncertainty around many parameters.

Recommend Documents


1
1 Data Quality Issues Modeling Tools

Modeling Intruder behavior Partial Data Source 1 Pointers from Research on

on the alignment of source code quality perspectives
On the Alignment of Source Code

On the Alignment of Source Code Quality Perspectives through Experimentation:

esm tools
esm-tools A tool for

esm-tools A tool for Earth-System-Modellers Nadine Wieters, Dirk Barbi, Luisa

airport source data committee airport source data
Airport Source Data Committee Airport

Airport Source Data Committee Airport Source Data Committee Objectives:

big data for housing providers
Big Data for housing providers Jim

Big Data for housing providers Jim Vine 3Vs of Big Data Data science

source max pixel

We are Here Source: Max Pixel Source:

new perspectives for open source and free software from
New perspectives for Open Source and

Context What is wrong The Ouverture Competitiveness Cluster The Ouverture

straight from the source youth perspectives on school
Straight from the Source: Youth

Straight from the Source: Youth Perspectives on School-wide Positive Behavior

new data new perspectives
New Data, New Perspectives: What the

New Data, New Perspectives: What the New Child Outcomes Data Tell Us (and

technical and legal perspectives
Technical and Legal Perspectives

Technical and Legal Perspectives in Data Sharing Agreements

presenter disclosures
Presenter Disclosures Dr. Ronald

Presenter Disclosures Dr. Ronald Goldenberg Controversies in Dyslipidemia

urinary excretion of low and high molecular weight
Urinary excretion of low and high

May 6th 7th 2011 y Mario Negri Institute for Pharmacological Research

virtual clinics
Virtual Clinics Nxt. GeN. HealtH CaRe

Virtual Clinics Nxt. GeN. HealtH CaRe Contents 2 Urban and Rural Health

diab te de type 2 pr vention cardiovasculaire
Diabte de type 2 Prvention

Diabte de type 2 Prvention cardiovasculaire JUIN 2016 Vzw Farmaka asbl

diabetes
Diabetes Haringey Public Health

Diabetes Haringey Public Health performance update CCG Governing Body meeting

new treatments for chronic hepatitis b
New Treatments for Chronic Hepatitis B

New Treatments for Chronic Hepatitis B Prof. Henry LY Chan Head, Division of

standards of
Standards of Diabetes 2019 Medical

6/13/2019 Practical Application of the Updated American Diabetes Association

polypharmacy decision support mobile app
Polypharmacy Decision Support Mobile

Polypharmacy Decision Support Mobile App Webinar Integrated Care Matters

c hronic a lcohol a buse
C HRONIC A LCOHOL A BUSE Group 2

C HRONIC A LCOHOL A BUSE Group 2 Samantha Benjamin, Sara Levy, & James

2012 2012 flor lorida y you outh th su subst bstance ce a
2012 2012 FLOR LORIDA Y YOU OUTH

2012 2012 FLOR LORIDA Y YOU OUTH TH SU SUBST BSTANCE CE A ABU BUSE

wobbly but still standing
Wobbly, But Still Standing

Wobbly, But Still Standing Recognizing, Understanding, and Helping the

substance use in montana
SUBSTANCE USE IN MONTANA Overview:

SUD SUMMIT | NOVEMBER 7TH, 2017 SUBSTANCE USE IN MONTANA Overview: Scope of